Novo Nordisk’s Saxenda Initially Positioned For Private Patients In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Obese patients who are severely ill with a high BMI and co-morbidities, and who are highly motivated to try a new therapy and willing to pay for it out-of-pocket, will be targeted for Saxenda.
You may also be interested in...
A Busy Year-End, In Brief: December Brings Slate Of Approvals, And Setbacks
In addition to a spate of FDA approvals closing out the year, Roche contended with trial failures and Actavis received a “complete response” letter for its nebivolol/valsartan combination.
Sanofi’s Rimonabant Off The European Market; CHMP Finds Risk Management Plan Does Not Adequately Address Depression
Acomplia use doubles risk of psychiatric disorders in overweight patients, European review finds.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.